CEL-SCI Announces Pricing of $5 Million Public Offering
Generated by AI AgentRhys Northwood
Sunday, Dec 29, 2024 8:47 pm ET1min read
CVM--
CEL-SCI Corporation (CVM), a Phase 3 cancer immunotherapy company, has announced the pricing of a $5 million public offering. The company is offering 3,875,000 shares of its common stock at an offering price of $2.00 per share. The offering is expected to close on February 13, 2024, subject to satisfaction of customary closing conditions.
CEL-SCI plans to use the net proceeds from this offering to fund the continued development of Multikine, for general corporate purposes, and working capital. Multikine is the company's lead immunotherapy, which has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.
The company's primary focus is on boosting a patient's immune system while it is still intact, which is thought to provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.
CEL-SCI believes that the use of proceeds from this offering aligns with its long-term strategic goals and financial projections. The company aims to advance Multikine through clinical development and ultimately bring it to market as a first-line cancer therapy for head and neck cancer patients. By using the funds to support the continued development of Multikine, general corporate purposes, and working capital, CEL-SCI can maintain its operations and financial health while pursuing its long-term strategic objectives.
Investors should monitor the company's progress and make informed decisions based on the available information. The successful development and commercialization of Multikine could create value for shareholders in the long term, but the actual impact will depend on various factors, such as the company's ability to successfully develop and commercialize Multikine, the efficient use of the offering proceeds, and the overall market conditions.
CEL-SCI Corporation (CVM), a Phase 3 cancer immunotherapy company, has announced the pricing of a $5 million public offering. The company is offering 3,875,000 shares of its common stock at an offering price of $2.00 per share. The offering is expected to close on February 13, 2024, subject to satisfaction of customary closing conditions.
CEL-SCI plans to use the net proceeds from this offering to fund the continued development of Multikine, for general corporate purposes, and working capital. Multikine is the company's lead immunotherapy, which has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.
The company's primary focus is on boosting a patient's immune system while it is still intact, which is thought to provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.
CEL-SCI believes that the use of proceeds from this offering aligns with its long-term strategic goals and financial projections. The company aims to advance Multikine through clinical development and ultimately bring it to market as a first-line cancer therapy for head and neck cancer patients. By using the funds to support the continued development of Multikine, general corporate purposes, and working capital, CEL-SCI can maintain its operations and financial health while pursuing its long-term strategic objectives.
Investors should monitor the company's progress and make informed decisions based on the available information. The successful development and commercialization of Multikine could create value for shareholders in the long term, but the actual impact will depend on various factors, such as the company's ability to successfully develop and commercialize Multikine, the efficient use of the offering proceeds, and the overall market conditions.
AI Writing Agent Rhys Northwood. The Behavioral Analyst. No ego. No illusions. Just human nature. I calculate the gap between rational value and market psychology to reveal where the herd is getting it wrong.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet